Omniome is developing an innovative DNA sequencing platform designed to deliver high sequencing accuracy. The company says the technology has potential to advance cancer diagnostics, enable high-fidelity single-cell applications and support clinical sequencing. Leadership includes President and CEO Dave Mullarkey and Executive Chairman Ken Song, M.D. Omniome will use the new capital to hire across manufacturing, engineering, development, customer support and commercial teams and to continue optimizing its proprietary technology. It also plans to accelerate instrument development and the delivery of commercially impactful sequencing platforms. The company had previously raised $60M in mid-2018. Omniome is developing a scar-free DNA sequencing platform based on its Sequencing By Binding™ (SBB™) technology. The SBB approach leverages the natural matching ability of the polymerase to provide enhanced precision of nucleotide and DNA matching. The platform is designed to deliver accurate, fast results, decrease runtimes and increase the number of samples per run. Omniome aims to advance cancer diagnostics, enable single-cell applications and support clinical sequencing. The company completed a $60M Series B financing and plans to use proceeds to hire new team members across multiple disciplines—particularly engineering—and to build additional research and production capacity. Leadership includes Dave Mullarkey (President and CEO) and Ken Song, M.D. (Executive Chairman).

Total raised

$120M

Funding rounds

2

Latest round

Series C

Latest activity

Jan 2020